Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network
- DOI
- 10.33393/grhta.2024.3094
- Published
- 2024-07-29
- Container
- Global and Regional Health Technology Assessment
- Publisher
- Aboutscience Srl
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.33393/grhta.2024.3094,
title = {Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network},
author = {Daniela Segala and Marco Barbieri and Mariachiara Di Nuzzo and Melissa Benazzi and Aurora Bonazza and Francesca Gentili and Kristian Scolz and Anna Marra and Rosario Cultrera},
year = {2024},
journal = {Global and Regional Health Technology Assessment},
doi = {10.33393/grhta.2024.3094},
url = {https://doi.org/10.33393/grhta.2024.3094}
}RIS
TY - JOUR TI - Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network AU - Daniela Segala AU - Marco Barbieri AU - Mariachiara Di Nuzzo AU - Melissa Benazzi AU - Aurora Bonazza AU - Francesca Gentili AU - Kristian Scolz AU - Anna Marra AU - Rosario Cultrera PY - 2024 JO - Global and Regional Health Technology Assessment DO - 10.33393/grhta.2024.3094 UR - https://doi.org/10.33393/grhta.2024.3094 ER -
APA
Segala, D., Barbieri, M., Nuzzo, M. D., Benazzi, M., Bonazza, A., Gentili, F., Scolz, K., Marra, A., & Cultrera, R. (2024). Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network. Global and Regional Health Technology Assessment. https://doi.org/10.33393/grhta.2024.3094
Source records
- crossref · retrieved 2026-09-27T10:43:11.380Z